B6-hCCR8 Mouse
Product Name
B6-hCCR8 Mouse
Product ID
C001808
Strain Name
C57BL/6NCya-Ccr8tm1(hCCR8)/Cya
Backgroud
C57BL/6NCya
Status
When using this mouse strain in a publication, please cite “B6-hCCR8 Mouse (Catalog C001808) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
CCR8
Gene Alias
CY6, TER1, CCR-8, CKRL1, CDw198, CMKBR8, GPRCY6, CMKBRL2, CC-CKR-8
NCBI ID
Chromosome
Chr 3 (Human)
MGI ID
Datasheet
Strain Description
The CCR8 gene encodes the C-C chemokine receptor type 8, a 41 kDa G-protein coupled receptor with seven transmembrane regions. This protein functions as a receptor for the chemokine CCL1 (also known as I-309) and is involved in cell migration, particularly for various immune cell types, and thymic cell apoptosis. CCR8 expression is notably found in the thymus and is also highly expressed on subsets of CD4+ memory T lymphocytes (including Th2 effector and regulatory T cells or Tregs), natural killer T (NKT) cells, macrophages, monocytes, and monocyte-derived dendritic cells [1]. Its expression is particularly relevant in inflammatory settings, where it guides immune cells to sites of inflammation and infection, such as in the lungs in asthma, and in the skin in atopic dermatitis [2]. Associated diseases and conditions include allergic disorders (like asthma and atopic dermatitis) due to its role in promoting Th2-biased immune responses, various cancers (e.g., malignant melanoma, hepatocellular carcinoma, cutaneous T-cell lymphomas) where it is highly expressed on tumor-infiltrating Tregs contributing to an immunosuppressive tumor microenvironment, and chronic inflammatory conditions such as chronic obstructive pulmonary disease (COPD) and potentially multiple sclerosis (MS) [3]. CCR8 also acts as an alternative co-receptor for HIV-1 infection [4].
The B6-hCCR8 mouse is a humanized model, constructed by replacing the coding sequences of the endogenous mouse Ccr8 gene with the coding sequences of the human CCR8 gene. B6-hCCR8 mice can be used for research into the pathogenesis of allergic disorders, various cancers, chronic inflammatory conditions, and HIV-1 infection, as well as for the screening, development, and safety evaluation of CCR8-targeted drugs.
Reference
Wen Y, Xia Y, Yang X, Li H, Gao Q. CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells. Trends Immunol. 2025 Feb;46(2):153-165.
Islam SA, Ling MF, Leung J, Shreffler WG, Luster AD. Identification of human CCR8 as a CCL18 receptor. J Exp Med. 2013 Sep 23;210(10):1889-98.
Moser B. Chemokine Receptor-Targeted Therapies: Special Case for CCR8. Cancers (Basel). 2022 Jan 20;14(3):511.
Cashin K, Jakobsen MR, Sterjovski J, Roche M, Ellett A, Flynn JK, Borm K, Gouillou M, Churchill MJ, Gorry PR. Linkages between HIV-1 specificity for CCR5 or CXCR4 and in vitro usage of alternative coreceptors during progressive HIV-1 subtype C infection. Retrovirology. 2013 Sep 16;10:98.
Strain Strategy
The sequences from the ATG start codon to the TAA stop codon of the endogenous mouse Ccr8 gene were replaced with the sequences from the ATG start codon to the TGA stop codon of the human CCR8 gene.
Figure 1. Gene editing strategy of B6-hCCR8 Mice.
Application Area
CCR8-targeted drug screening, development, and evaluation;
Research on the pathological mechanisms and therapeutic approaches of allergic disorders (like asthma and atopic dermatitis);
Research on the pathological mechanisms and therapeutic approaches of various cancers (e.g., malignant melanoma, hepatocellular carcinoma, cutaneous T-cell lymphomas);
Research on the pathological mechanisms and therapeutic approaches of chronic inflammatory conditions such as chronic obstructive pulmonary disease (COPD) and potentially multiple sclerosis (MS);
Research on HIV-1 infection.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
